Ratings by RBC Capital (Douglas Miehm)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/8/2026 | Ligand Pharma | LGND | Maintain | Outperform (N/A) |
|
Details | ||
| 4/28/2026 | Ligand Pharma | LGND | Maintain | Outperform (N/A) |
|
Details | ||
| 3/17/2026 | Bausch & Lomb Corp. | BLCO | Maintain | Outperform (N/A) |
|
Details | ||
| 3/2/2026 | MannKind | MNKD | Downgrade | Sector Perform (Outperform) |
3.24 (3.36) |
3.7% | Details | |
| 2/27/2026 | MannKind | MNKD | Downgrade | Sector Perform (Outperform) |
7.00 (3.24) |
-53.71% | Details | |
| 1/27/2026 | Bausch & Lomb Corp. | BLCO | Maintain | Outperform (N/A) |
|
Details | ||
| 12/10/2025 | Ligand Pharma | LGND | Maintain | Outperform (N/A) |
|
Details | ||
| 11/25/2025 | Ligand Pharma | LGND | Maintain | Outperform (N/A) |
|
Details | ||
| 11/14/2025 | Bausch & Lomb Corp. | BLCO | Maintain | Outperform (N/A) |
|
Details | ||
| 11/10/2025 | MannKind | MNKD | Maintain | Outperform (N/A) |
|
Details | ||
| 11/10/2025 | Ligand Pharma | LGND | Maintain | Outperform (N/A) |
|
Details | ||
| 11/5/2025 | Aurinia Pharmaceuticals | AUPH | Downgrade | Sector Perform (Outperform) |
13.17 (15.67) |
18.98% | Details | |
| 8/26/2025 | MannKind | MNKD | Maintain | Outperform (N/A) |
|
Details | ||
| 8/8/2025 | Ligand Pharma | LGND | Maintain | Outperform (N/A) |
|
Details | ||
| 8/7/2025 | MannKind | MNKD | Maintain | Outperform (N/A) |
|
Details | ||
| 8/1/2025 | Aurinia Pharmaceuticals | AUPH | Maintain | Outperform (N/A) |
|
Details | ||
| 7/23/2025 | MannKind | MNKD | Maintain | Outperform (N/A) |
|
Details | ||
| 7/15/2025 | Bausch & Lomb Corp. | BLCO | Maintain | Outperform (N/A) |
|
Details | ||
| 4/4/2025 | Bausch & Lomb Corp. | BLCO | Maintain | Outperform (N/A) |
|
Details | ||
| 2/28/2025 | Ligand Pharma | LGND | Maintain | Outperform (N/A) |
|
Details | ||
| 2/28/2025 | Aurinia Pharmaceuticals | AUPH | Maintain | Outperform (N/A) |
|
Details | ||
| 2/20/2025 | Bausch & Lomb Corp. | BLCO | Maintain | Outperform (N/A) |
|
Details | ||
| 12/11/2024 | Ligand Pharma | LGND | Maintain | Outperform (N/A) |
|
Details | ||
| 12/3/2024 | Ligand Pharma | LGND | Maintain | Outperform (N/A) |
|
Details | ||
| 11/11/2024 | Aurinia Pharmaceuticals | AUPH | Maintain | Outperform (N/A) |
|
Details | ||
| 7/30/2024 | Ligand Pharma | LGND | New Coverage | Outperform (N/A) |
107.14 (234.40) |
118.78% | Details | |
| 1/3/2023 | Aurinia Pharmaceuticals | AUPH | Maintain | Outperform (N/A) |
|
Details | ||
| 11/4/2022 | Aurinia Pharmaceuticals | AUPH | Maintain | Outperform (N/A) |
|
Details | ||
| 8/5/2022 | Aurinia Pharmaceuticals | AUPH | Maintain | Outperform (N/A) |
|
Details | ||
| 4/28/2022 | Aurinia Pharmaceuticals | AUPH | Maintain | Outperform (N/A) |
|
Details | ||
| 3/1/2022 | Aurinia Pharmaceuticals | AUPH | Maintain | Outperform (N/A) |
|
Details | ||
| 2/23/2022 | Aurinia Pharmaceuticals | AUPH | Maintain | Outperform (N/A) |
|
Details | ||
| 10/26/2021 | Aurinia Pharmaceuticals | AUPH | Maintain | Outperform (N/A) |
|
Details | ||
| 5/7/2021 | Aurinia Pharmaceuticals | AUPH | Maintain | Outperform (N/A) |
|
Details | ||
| 1/26/2021 | Aurinia Pharmaceuticals | AUPH | Maintain | Outperform (N/A) |
|
Details | ||
| 12/5/2019 | Aurinia Pharmaceuticals | AUPH | Maintain | Outperform (N/A) |
|
Details | ||
| 3/20/2019 | Aurinia Pharmaceuticals | AUPH | Maintain | Outperform (N/A) |
|
Details | ||
| 10/23/2018 | Shire | SHPG | Maintain | Outperform (N/A) |
|
Details |
